• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection.

作者信息

Raqib Rubhana, Venkatesan Malabi

机构信息

Infectious Diseases Division, icddr,b, Dhaka, Bangladesh.

Department of Enteric Infections, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Maryland, USA (recently retired).

出版信息

EBioMedicine. 2021 Apr;66:103343. doi: 10.1016/j.ebiom.2021.103343. Epub 2021 Apr 16.

DOI:10.1016/j.ebiom.2021.103343
PMID:33873142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8082079/
Abstract
摘要

相似文献

1
Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection.志贺氏菌结合疫苗在人体对照模型中的疗效试验及潜在的保护性免疫相关因素
EBioMedicine. 2021 Apr;66:103343. doi: 10.1016/j.ebiom.2021.103343. Epub 2021 Apr 16.
2
How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?受控人体感染模型如何加速针对志贺氏菌的疫苗的临床开发和政策途径？
Vaccine. 2019 Aug 7;37(34):4778-4783. doi: 10.1016/j.vaccine.2019.03.036.
3
Classical and novel strategies to develop a glycoconjugate vaccine: from concept to efficacy in human.经典与新型策略开发糖缀合物疫苗：从概念到人体疗效。
Hum Vaccin Immunother. 2019;15(6):1338-1356. doi: 10.1080/21645515.2019.1606972.
4
Shigella vaccine development: prospective animal models and current status.志贺氏菌疫苗研发：前瞻性动物模型与现状
Curr Pharm Biotechnol. 2013;14(10):903-12. doi: 10.2174/1389201014666131226123900.
5
Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development.肠致病性大肠杆菌（ETEC）和志贺氏菌感染中抗原特异性 T 和 B 细胞在全身和黏膜免疫反应中的作用，及其作为疫苗开发中保护相关性的潜力。
Vaccine. 2019 Aug 7;37(34):4787-4793. doi: 10.1016/j.vaccine.2019.03.040. Epub 2019 Jun 20.
6
A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.一个用于指导疫苗设计的志贺氏菌免疫的临床参数化数学模型。
PLoS One. 2018 Jan 5;13(1):e0189571. doi: 10.1371/journal.pone.0189571. eCollection 2018.
7
Live-attenuated Shigella vaccines.减毒活志贺氏菌疫苗
Expert Rev Vaccines. 2006 Oct;5(5):669-86. doi: 10.1586/14760584.5.5.669.
8
Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward.人类针对志贺氏菌和肠产毒性大肠杆菌的免疫反应：当前进展和未来方向。
Vaccine. 2017 Dec 14;35(49 Pt A):6803-6806. doi: 10.1016/j.vaccine.2017.05.034. Epub 2017 May 27.
9
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.在健康成年志愿者中评估针对福氏 2a 志贺菌的合成糖缀合物疫苗的安全性和免疫原性：一项 1 期、剂量递增、单盲、随机、安慰剂对照研究。
Lancet Infect Dis. 2021 Apr;21(4):546-558. doi: 10.1016/S1473-3099(20)30488-6. Epub 2020 Nov 10.
10
Status of vaccine research and development for Shigella.志贺氏菌疫苗研发状况
Vaccine. 2016 Jun 3;34(26):2887-2894. doi: 10.1016/j.vaccine.2016.02.075. Epub 2016 Mar 12.

引用本文的文献

1
Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.针对福氏志贺菌 6 型的志贺氏菌结合疫苗的开发，该疫苗具有免疫原性，能提供针对强毒力挑战的保护。
Vaccine. 2024 Oct 24;42(24):126263. doi: 10.1016/j.vaccine.2024.126263. Epub 2024 Aug 31.
2
Vaccines: The Continuing Unmet Challenge.疫苗：持续未被满足的挑战。
Int J Mol Sci. 2024 Apr 13;25(8):4329. doi: 10.3390/ijms25084329.
3
Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.利用新型平台偶联技术——丁烯二酸化学法，研制针对福氏 2a 亚型和福氏 3a 亚型志贺菌的志贺菌结合疫苗。
Vaccine. 2023 Jul 31;41(34):4967-4977. doi: 10.1016/j.vaccine.2023.06.052. Epub 2023 Jul 1.

本文引用的文献

1
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.人体挑战研究与志贺氏菌生物缀合疫苗：临床疗效和保护相关因素分析。
EBioMedicine. 2021 Apr;66:103310. doi: 10.1016/j.ebiom.2021.103310. Epub 2021 Apr 13.
2
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.人体挑战研究中福氏 2a 志贺氏菌双价结合疫苗免疫反应特征。
EBioMedicine. 2021 Apr;66:103308. doi: 10.1016/j.ebiom.2021.103308. Epub 2021 Apr 1.
3
Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints.志贺氏菌感染人体模型专家共识报告：临床终点。
Clin Infect Dis. 2019 Dec 9;69(Suppl 8):S591-S595. doi: 10.1093/cid/ciz891.
4
Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.志贺菌和肠产毒性大肠杆菌腹泻导致的发病和死亡：1990-2016 年全球疾病负担研究。
Lancet Infect Dis. 2018 Nov;18(11):1229-1240. doi: 10.1016/S1473-3099(18)30475-4. Epub 2018 Sep 25.
5
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.志贺氏菌人体感染控制模型的临床终点：呼吁标准化和制定疾病严重程度评分
PLoS One. 2018 Mar 28;13(3):e0194325. doi: 10.1371/journal.pone.0194325. eCollection 2018.
6
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.1-4 岁以色列儿童中志贺氏菌 O 特异性多糖结合物的年龄相关疗效。
Vaccine. 2010 Mar 2;28(10):2231-2235. doi: 10.1016/j.vaccine.2009.12.050. Epub 2010 Jan 5.
7
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.一项针对年轻成年人的新型宋内志贺氏菌结合疫苗的双盲疫苗对照随机疗效试验。
Lancet. 1997 Jan 18;349(9046):155-9. doi: 10.1016/S0140-6736(96)06255-1.